# idiopathic pulmonary fibrosis (IPF) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 3867
- Completion tokens: 24405
- Reasoning tokens: 
- Total tokens: 28272
- API requests reported: 
- Elapsed seconds: 261.915
- Final benchmark system: raw; file rank 5/5; original repeat 5; model vendor: DeepSeek

---
## Important data-quality caveat

The prognostic table contains several HR values that are biologically implausible, including HR = 5.18e21, HR = 1.93e-22, with P = 0 and FDR = 0. These include control probes, unannotated transcripts, and genes with very low or absent expression in lung tissue:

- `CONTROL_A_33_P3222196`, `CONTROL_A_33_P3345409`
- `HCN4`, `OR2M2`, `IHH`, `DYDC2`, `MIR221`, `FAM75A2`, `DKFZP434L187`, `XLOC_003303`

These are more consistent with zero-inflation, quasi-complete separation, or unstable Cox estimates than with meaningful protective or risk biology. I therefore exclude them from biological program interpretation, while noting that they must be resolved by expression-level QC and model diagnostics.

The one non-extreme protective signal, `LOC100128226` (HR = 0.007, FDR = 4.8e-35), is interesting but poorly annotated and should be treated as an uncharacterized candidate, not as evidence for a protective biological program.

---

## 1. Overall biological interpretation

After excluding likely technical artifacts, this prognostic transcriptome in idiopathic pulmonary fibrosis lung tissue is dominated by **risk-associated genes**: higher tissue expression is associated with increased all-cause mortality. The overall picture is not a single linear pathway but a coordinated, active tissue-repair and inflammatory state in which:

- Alveolar epithelial cells show aberrant differentiation, mucin/secretory metaplasia, and stress-related keratin expression;
- Innate immune cells, especially neutrophils and macrophages, are recruited and activated through alarmins and chemokines;
- Extracellular matrix remodeling and TGF-β/BMP signaling are active;
- Growth factor receptor tyrosine kinase signaling is engaged, including HGF–MET and NRG1–ErbB-related signals;
- Redox, oxidative stress, and metabolic adaptation pathways are induced.

This is best interpreted as an **active fibroproliferative and innate-immune tissue state** that carries poor prognosis, rather than as evidence for a protective or reparative gene program. Because the data come from bulk lung tissue, cell-composition shifts—such as increased neutrophils, macrophages, metaplastic epithelium, or fibroblasts—likely contribute substantially to the signal and cannot be separated from cell-intrinsic expression changes without further validation.

---

## 2. Core biological programs

No more than five major programs are described below. All are **risk-associated** in this dataset (HR > 1). No protective program with sufficient evidence was identifiable, aside from the uncharacterized `LOC100128226`.

### Program 1: DAMP/chemokine-driven innate immune activation

- **Direction:** Risk-associated
- **Supporting genes:** `S100A12`, `S100A14`, `SPP1`, `CXCL1`, `CXCR1`, `CCL7`, `SELL`, `CD177`, `MMP25`, `PROK2`, `STAB1`, `MERTK`
- **Best standardized pathway:** Hallmark “Inflammatory response”; GO:0050900 “leukocyte migration”; Reactome “Chemokine receptors bind chemokine”
- **Interpretation:** S100A12 is a neutrophil-derived alarmin and RAGE ligand; CXCL1/CXCR1, CCL7, PROK2, SELL, CD177, and MMP25 are strongly linked to neutrophil and monocyte recruitment or granulocytic activity. SPP1, STAB1, and MERTK point toward activated pro-fibrotic macrophages. Together these genes indicate that a myeloid-dominant inflammatory niche is a major mortality-associated feature.
- **Strength and limitations:** Supported by many independent genes across the same biological theme. However, several of these genes are also cell-type markers, so the signal may partly reflect higher neutrophil or macrophage abundance in fatal IPF tissue.

### Program 2: Aberrant epithelial repair with mucinous/secretory metaplasia

- **Direction:** Risk-associated
- **Supporting genes:** `MUC1`, `MUC21`, `CEACAM6`, `CEACAM7`, `AGR3`, `MAL2`, `MARCKS`, `GALNT14`, `SFTPB`, `SFTA2`, `SLC34A2`, `PRSS8`, `KRT17`, `KRT23`, `SPRR1A`
- **Best standardized pathway:** GO:0030855 “epithelial cell differentiation”; GO:0031424 “keratinization”; Reactome “O-linked glycosylation of mucins”
- **Interpretation:** Mucins and CEACAM genes indicate aberrant mucous or airway epithelial differentiation; KRT17, KRT23, and SPRR1A suggest squamous or basal cell metaplasia; SFTPB, SFTA2, and SLC34A2 are alveolar type II/secretory epithelial markers. This is consistent with failed alveolar regeneration and abnormal epithelial remodeling.
- **Strength and limitations:** A large and coherent set of epithelial genes. The main limitation is that these are also cell-type markers, and bulk tissue cannot distinguish true pathway activation from replacement of normal alveolar epithelium by metaplastic or injured epithelium.

### Program 3: ECM remodeling and TGF-β/BMP fibrosis signaling

- **Direction:** Risk-associated
- **Supporting genes:** `HTRA1`, `EFEMP1`, `FHL2`, `FBLIM1`, `BMP6`, `CHST15`, `HS3ST1`, `TPST1`, `SPP1`
- **Best standardized pathway:** GO:0030198 “extracellular matrix organization”; Hallmark “TGF-β signaling”; Reactome “Extracellular matrix organization”
- **Interpretation:** HTRA1 and EFEMP1 are secreted ECM-remodeling/proteolytic proteins; FHL2 can act as a Smad coactivator in TGF-β signaling; CHST15 and HS3ST1 modify proteoglycans and growth factor availability; SPP1 is a matricellular protein with pro-fibrotic roles. This program points toward active fibrogenesis and matrix turnover.
- **Strength and limitations:** Multiple independent genes support an ECM/TGF-β-related theme. However, BMP6 and HTRA1 can have context-dependent, sometimes anti-fibrotic, effects, so the direction is not necessarily equivalent to “TGF-β activation.”

### Program 4: Receptor tyrosine kinase and regenerative stress signaling

- **Direction:** Risk-associated
- **Supporting genes:** `MET`, `HGF`, `NRG1`, `SPRY2`, `RGL1`, `PTP4A3`, `MERTK`
- **Best standardized pathway:** Reactome “Signaling by Receptor Tyrosine Kinases”; GO:0007169 “transmembrane receptor protein tyrosine kinase signaling pathway”
- **Interpretation:** MET is the receptor for HGF; NRG1 signals through ErbB receptors; SPRY2 is a negative-feedback regulator of RTK signaling; RGL1 and PTP4A3 are downstream modulators of Ras/phosphatase-related signaling. This resembles an epithelial repair/regenerative stress response.
- **Strength and limitations:** HGF–MET is a direct ligand–receptor pair. However, HGF–MET signaling is canonically protective and anti-fibrotic in many lung injury models. The risk association here therefore suggests the signal may be a compensatory response to severe injury rather than a causal driver, or that its role is cell-type- and context-dependent.

### Program 5: Oxidative stress, redox, and metabolic adaptation

- **Direction:** Risk-associated
- **Supporting genes:** `SLC7A11`, `SOD3`, `SLC39A8`, `SLC6A8`, `STEAP4`, `ALDH1A3`, `CYP4F3`
- **Best standardized pathway:** Hallmark “Reactive Oxygen Species Pathway”; GO:0006979 “response to oxidative stress”
- **Interpretation:** SLC7A11 is the cystine/glutamate antiporter that protects against ferroptosis; SOD3 is an extracellular antioxidant enzyme; STEAP4 and SLC39A8 link inflammation, zinc/iron handling, and oxidoreductase activity; SLC6A8 and CYP4F3 point toward altered metabolic and lipid handling. This may reflect a broader oxidative and metabolic stress response in severely fibrotic lung tissue.
- **Strength and limitations:** Supported by several redox-related genes, but functionally heterogeneous. Some genes may also reflect specific cell populations rather than a unified metabolic program.

---

## 3. Key genes and interaction modules

The list below is limited to ten candidates or modules that deserve particular attention.

### 1. SPP1 / osteopontin

- **Direction:** HR = 3.40, FDR = 4e-5
- **Biological role:** Osteopontin is a matricellular cytokine expressed by macrophages and epithelial cells; it promotes inflammation, fibrosis, and cell survival.
- **Relationship evidence:** In this dataset, co-expressed within a broader myeloid/inflammatory program. Literature supports SPP1 binding to integrins and CD44, but that is not directly demonstrated by the current data.

### 2. S100A12 / S100A14

- **Direction:** HR = 2.53 and 2.57, respectively
- **Biological role:** S100A12 is a granulocyte alarmin and RAGE ligand; S100A14 is less well characterized but belongs to the same calcium-binding S100 family.
- **Relationship evidence:** Gene-family and likely co-expression relationship. No direct physical interaction between S100A12 and S100A14 is established here.

### 3. MERTK

- **Direction:** HR = 3.70, FDR = 1.05e-5
- **Biological role:** TAM receptor tyrosine kinase involved in macrophage efferocytosis, inflammation resolution, and pro-fibrotic macrophage polarization.
- **Relationship evidence:** Functional receptor–ligand relationships with Gas6/Protein S are known in the literature, but no ligand evidence is provided by this dataset.

### 4. HTRA1

- **Direction:** HR = 4.30, FDR = 2.57e-6
- **Biological role:** Secreted serine protease that regulates ECM remodeling and TGF-β/BMP bioavailability.
- **Relationship evidence:** Likely regulatory interaction with TGF-β/BMP family proteins, but this is inferred from literature and not directly measured here.

### 5. MUC1 / CEACAM epithelial module

- **Direction:** MUC1 HR = 2.32; MUC21 HR = 2.10; CEACAM6 HR = 2.66; CEACAM7 HR = 2.31
- **Biological role:** Mucinous and secretory epithelial metaplasia; likely reflects aberrant airway-like differentiation in IPF lung tissue.
- **Relationship evidence:** Pathway co-membership and likely co-regulation. CEACAM family members can interact homophilically in the literature, but the current data only support co-expression/co-abundance.

### 6. MET / HGF / SPRY2 RTK module

- **Direction:** MET HR = 2.53; HGF HR = 2.93; SPRY2 HR = 3.26
- **Biological role:** HGF–MET signaling is a classic epithelial repair pathway; SPRY2 is an inducible negative-feedback regulator of RTK signaling.
- **Relationship evidence:** HGF–MET is a direct ligand–receptor physical interaction. SPRY2 regulation of RTK signaling is a regulatory interaction, not a direct physical HGF–SPRY2 interaction.

### 7. CXCR1 / CXCL1 / CD177 / MMP25 neutrophil module

- **Direction:** CXCR1 HR = 3.28; CXCL1 HR = 2.99; CD177 HR = 2.72; MMP25 HR = 3.26
- **Biological role:** Neutrophil recruitment, degranulation, and tissue damage.
- **Relationship evidence:** Pathway co-membership in chemokine/inflammatory signaling. Importantly, CXCL1 is canonically more selective for CXCR2 than CXCR1, so a direct CXCL1–CXCR1 physical interaction should not be assumed. CD177 and MMP25 are neutrophil markers, likely reflecting neutrophil abundance.

### 8. FHL2

- **Direction:** HR = 2.76, FDR = 2.76e-6
- **Biological role:** LIM-only adaptor protein that can integrate TGF-β/Smad and Wnt signaling, with potential relevance to fibroblast activation.
- **Relationship evidence:** Literature supports FHL2–Smad regulatory or physical association, but the current dataset only supports a prognostic association and pathway co-membership.

### 9. SLC7A11

- **Direction:** HR = 3.52, FDR = 1.09e-5
- **Biological role:** Cystine/glutamate antiporter and ferroptosis suppressor; part of the oxidative stress response.
- **Relationship evidence:** Co-functional with SOD3, STEAP4, and SLC39A8 in redox/metabolic pathways, but no direct physical interaction is indicated.

### 10. LOC100128226

- **Direction:** HR = 0.007, FDR = 4.8e-35
- **Biological role:** Unknown; likely non-coding or poorly annotated transcript.
- **Relationship evidence:** No interaction or functional evidence is available. It is a high-priority unknown because it is the only non-artifact protective signal, but it should be treated as exploratory.

---

## 4. Validation priorities

### Priority 1: Cell-composition and tissue-context validation

- **Classification:** Confounding / composition check
- **Why:** Many risk genes are canonical markers of neutrophils, macrophages, alveolar type II cells, or metaplastic airway epithelium. Bulk lung tissue in IPF has highly variable composition.
- **Current evidence:** HR > 2 for cell-type marker genes such as CD177, MMP25, S100A12, SPP1, MERTK, SFTPB, SLC34A2, MUC1, and KRT17.
- **External evidence:** IPF single-cell and spatial studies show increased SPP1+ macrophages, myeloid infiltration, and aberrant basal/epithelial cell states, which supports a strong cell-composition contribution.
- **Next step:** Single-cell RNA-seq, spatial transcriptomics, and cell-type deconvolution of bulk data, then re-estimate prognostic associations with cell-composition covariates.
- **Conclusion status:** Supported hypothesis—cell composition likely contributes substantially to the bulk prognostic signal.

### Priority 2: Functional testing of SPP1 and MERTK

- **Classification:** Mechanistic hypothesis / therapeutic target
- **Why:** Both are biologically plausible myeloid profibrotic mediators, and both show strong risk associations in this dataset.
- **Current evidence:** SPP1 HR = 3.40; MERTK HR = 3.70; both appear in the same immune/macrophage risk program.
- **External evidence:** Osteopontin/SPP1 is known to promote fibrosis in animal models. MERTK can either promote resolution of inflammation or contribute to fibrosis depending on context, so the direction is less certain.
- **Next step:** Neutralize SPP1 or inhibit MERTK in bleomycin-induced pulmonary fibrosis models, or use conditional myeloid-specific knockouts.
- **Conclusion status:** SPP1: supported hypothesis. MERTK: supported but context-dependent hypothesis.

### Priority 3: MUC1/CEACAM as prognostic biomarkers

- **Classification:** Biomarker
- **Why:** The mucin/CEACAM epithelial module is large, reproducible across many genes, and related to aberrant epithelial repair. MUC1 is measurable in blood as CA15-3.
- **Current evidence:** MUC1, MUC21, CEACAM6, CEACAM7, AGR3, and GALNT14 all carry risk-associated HRs.
- **External evidence:** Mucin-related biology is strongly linked to IPF, particularly through MUC5B genetic risk. Soluble MUC1/CA15-3 has been studied as an IPF biomarker.
- **Next step:** Measure plasma or sputum MUC1/CEACAM6 in IPF cohorts and test association with transplant-free survival after adjustment for FVC, DLCO, and GAP stage.
- **Conclusion status:** MUC1: supported hypothesis. CEACAM/mucin module: exploratory.

### Priority 4: Resolve direction and cell context of HGF/MET/NRG1 signaling

- **Classification:** Mechanistic hypothesis
- **Why:** HGF–MET is canonically anti-fibrotic, yet HGF, MET, and SPRY2 are risk-associated here. This is one of the most important interpretational conflicts in the dataset.
- **Current evidence:** HGF HR = 2.93; MET HR = 2.53; SPRY2 HR = 3.26.
- **External evidence:** HGF is protective in many experimental lung fibrosis models, supporting a compensatory rather than maladaptive interpretation. However, sustained RTK signaling in the wrong cell type could also worsen fibrosis.
- **Next step:** Cell-type-specific MET deletion in alveolar epithelium or macrophages; measure phospho-MET/HGF activity in IPF tissue; use organoid or in vivo repair models.
- **Conclusion status:** Exploratory hypothesis. The current data do not distinguish compensation from causation.

### Priority 5: Technical validation of extreme HRs and LOC100128226

- **Classification:** Confounding / composition check
- **Why:** Extreme HR values and P = 0 values are statistically implausible and could distort downstream interpretation. LOC100128226 is the only protective candidate but is uncharacterized.
- **Current evidence:** Multiple genes/probes have HR values >1e21 or <1e-22 with FDR = 0.
- **External evidence:** None available for LOC100128226; extreme HRs are likely due to low expression or zero-inflated data.
- **Next step:** Re-examine raw expression values, filter low-expression genes, use stabilized Cox/penalized regression, and validate LOC100128226 by qRT-PCR in an independent IPF cohort.
- **Conclusion status:** The need for technical QC is established. The protective role of LOC100128226 is exploratory.

---

## 5. Evidence grounding

The following evidence types support the interpretation:

- **Direct input dataset evidence:** HR, P, and FDR values from the supplied table.
- **Pathway/ontology evidence:** Manually assigned GO/Reactome/Hallmark relationships based on known gene annotations. This is not a formal enrichment analysis and should be interpreted as annotation-based support.
- **Protein interaction/regulatory evidence:** HGF–MET is a well-established direct ligand–receptor physical interaction. SPRY2 is a known negative-feedback regulator of RTK signaling. FHL2–Smad interactions and CEACAM homophilic interactions are literature-supported but not established by this dataset.
- **Disease-association evidence:** Several genes, including SPP1, MUC1, MERTK, HTRA1, and CHST15, have prior literature associations with IPF or fibrosis. This is independent external evidence, but it may have influenced gene selection for interpretation.
- **Expression/tissue-specific evidence:** Bulk lung tissue expression is not cell-resolved; many risk genes are cell-type markers.
- **Genetic/clinical evidence:** The mucin program is indirectly supported by the well-known MUC5B IPF risk locus, but MUC5B is not in this dataset.
- **Drug/therapeutic evidence:** Some targets have existing investigational agents, but that does not by itself establish therapeutic relevance in IPF.

Where multiple sources converge, they are not fully independent. For example, literature knowledge of SPP1 as a pro-fibrotic gene overlaps with the decision to highlight SPP1 after seeing its HR. The strongest independent evidence is direct experimental interaction data, such as HGF–MET binding, but that does not prove causality in IPF prognosis.

---

## 6. Limitations and alternative explanations

### 1. Bulk tissue composition

IPF lung tissue contains highly variable amounts of alveolar epithelium, metaplastic airway epithelium, fibroblasts, myofibroblasts, macrophages, neutrophils, and lymphocytes. Many prognostic genes may simply mark more severe disease via higher abundance of a particular cell type. This is particularly concerning for genes like CD177, MMP25, S100A12, STAB1, MERTK, SFTPB, SLC34A2, and MUC1.

### 2. Technical artifacts and non-lung transcripts

The table contains control probes and extreme HRs that are not biologically plausible. Some nominally significant genes, such as MGAM, ACOX2, OR2M2, and HCN4, are not well-established lung-expressed transcripts. These may reflect annotation artifacts, low-level contamination, or unstable statistical estimates.

### 3. Missing clinical covariates

All-cause mortality in IPF is strongly associated with age, sex, baseline FVC, DLCO, GAP stage, smoking status, treatment exposure, and disease trajectory. Without covariate adjustment or an independent replication cohort, the reported HRs may reflect disease severity rather than independent molecular prediction.

### 4. Association-versus-causation ambiguity

Higher expression of HGF, SOD3, and SLC7A11 is typically considered protective or reparative in other contexts, yet these genes are risk-associated here. This suggests that the transcriptome may reflect compensatory responses to severe injury or the presence of the disease process itself, rather than the primary drivers of mortality.

### 5. Broad pathway overlap and lack of external validation

The identified programs are broad and overlap with general tissue injury, inflammation, and fibrosis. Without external validation, formal enrichment statistics, and comparison to other chronic lung diseases, the IPF-specificity and independent prognostic value of these programs remain uncertain.

---

## Final caution

These findings should be treated as hypothesis-generating. The risk-associated transcriptome in IPF lung tissue is biologically coherent, but the distinction between cell composition, compensatory injury responses, and causal disease-driver programs requires single-cell, spatial, and functional validation. No gene or pathway should be considered an established therapeutic target solely because it is significant in this prognostic analysis.
